Individuals with no prior history of dengue are at an increased risk of developing severe dengue infection should they receive DENGVAXIA vaccine and become infected with the dengue virus. Children under the age of six, including children with a prior history of dengue illness, may be at an increased risk of severe dengue illness and hospitalization if they are administered DENGVAXIA and become infected with any serotype of dengue.
DENGVAXIA vaccine is a live attenuated vaccine. Person who are severely immunocompromised may be at an increased risk of complications should they receive the vaccine.
Individuals with a prior history of allergic reaction to a previous dose of DENGVAXIA or to any of its ingredients may be at an increased risk of complications if administered the vaccine.
IMPORTANT NOTE: NVIC encourages you to become fully informed about Dengue and the Dengue vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
